Prostatype Genomics（PGO0）株式概要Prostatype Genomics ABは予後遺伝子検査の製造、販売、マーケティングを行っている。 詳細PGO0 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6リスク分析収益が 100 万ドル未満 ( SEK594K )過去5年間で収益は年間23.9%減少しました。 キャッシュランウェイが1年未満である 意味のある時価総額がありません ( €2M )+2 さらなるリスクすべてのリスクチェックを見るPGO0 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.0254.8k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-45m5m2016201920222025202620282031Revenue SEK 328.8kEarnings SEK 59.8kAdvancedSet Fair ValueView all narrativesProstatype Genomics AB (publ) 競合他社bioXXmedSymbol: DB:T5OMarket cap: €222.9kEpigenomicsSymbol: DB:ECXMarket cap: €763.0kGenetic AnalysisSymbol: DB:8V8Market cap: €42.7mDarwinSymbol: MUN:7V0Market cap: €68.4m価格と性能株価の高値、安値、推移の概要Prostatype Genomics過去の株価現在の株価SEK 0.02552週高値SEK 0.1952週安値SEK 0.014ベータ1.521ヶ月の変化-51.71%3ヶ月変化-66.58%1年変化-68.64%3年間の変化-99.85%5年間の変化-99.90%IPOからの変化-99.90%最新ニュースお知らせ • May 21Prostatype Genomics AB (publ), Annual General Meeting, Jun 22, 2026Prostatype Genomics AB (publ), Annual General Meeting, Jun 22, 2026, at 15:00 W. Europe Standard Time. Location: augustendalsvagen 20, nacka strand, Swedenお知らせ • Jan 09Prostatype Genomics U.S. Validation Study by Veterans Affairs (Va) Is PublishedProstatype Genomics announced that the study performed in USA under the leadership of professor Stephen Freedland at Department of Urology at Cedars-Sinai, and in association with the Durham Veteran Affairs Healthcare System, has been accepted and is published in the medical journal Prostate Cancer and Prostatic Diseases Veterans Affairs is one of the world's largest integrated health care systems where Cedars-Sinai is ranked among the top 10 most influential hospitals in USA. The study includes a diverse patient population, with a significant proportion of African American patients, which is crucial for ensuring the clinical utility of the test across a broad demographic setting. In summary the study results shows that Prostatype has a strong and significant predictive ability to identify the men that really has a high risk of dying from prostate cancer which is the type of clinical information that doctors and health care payers are looking for. Furthermore, also seen in other published studies, Prostatype significantly outperforms existing clinical prognostic tools adding additional clinical benefit for patients, doctors and health care providers. Notably, no significant difference was observed in the test's performance between African American and Caucasian patients, reinforcing Prostatype's robustness and reliability across different patient groups.お知らせ • May 16Prostatype Genomics AB (Publ) Announces Johan Waldhe Was Not Re-Elects, as He Had Declares That He Was Not Available for Re-ElectionProstatype Genomics AB (publ) at its annual general meeting held on 15 May 2025, approved Johan Waldhe was not re-elected, as he had declared that he was not available for re-election.お知らせ • Apr 16Prostatype Genomics AB (publ), Annual General Meeting, May 15, 2025Prostatype Genomics AB (publ), Annual General Meeting, May 15, 2025, at 15:00 W. Europe Standard Time. Location: at augustendalsvagen 20, 131 52 nacka strand, Swedenお知らせ • Apr 15Prostatype Genomics AB (Publ) Announces Johan Waldhe Not Available for Re-ElectionProstatype Genomics AB (publ) announced that Johan Waldhe has declared that he is not available for re-election due to other commitments.お知らせ • Mar 31Prostatype Genomics Announces Positive Preliminary Results for Primary Endpoints in U.S. Study with ProstatypeProstatype Genomics announced that preliminary results from the study conducted in the United States in collaboration with leading institutions shows promising results. Prostatype is a genomic test designed to improve risk stratification of patients diagnosed with non-metastatic prostate cancer. The study has a diverse patient population, with a significant proportion of African American patients, which is crucial for ensuring the clinical utility of the test in a patient population with multiple ethnicities.最新情報をもっと見るRecent updatesお知らせ • May 21Prostatype Genomics AB (publ), Annual General Meeting, Jun 22, 2026Prostatype Genomics AB (publ), Annual General Meeting, Jun 22, 2026, at 15:00 W. Europe Standard Time. Location: augustendalsvagen 20, nacka strand, Swedenお知らせ • Jan 09Prostatype Genomics U.S. Validation Study by Veterans Affairs (Va) Is PublishedProstatype Genomics announced that the study performed in USA under the leadership of professor Stephen Freedland at Department of Urology at Cedars-Sinai, and in association with the Durham Veteran Affairs Healthcare System, has been accepted and is published in the medical journal Prostate Cancer and Prostatic Diseases Veterans Affairs is one of the world's largest integrated health care systems where Cedars-Sinai is ranked among the top 10 most influential hospitals in USA. The study includes a diverse patient population, with a significant proportion of African American patients, which is crucial for ensuring the clinical utility of the test across a broad demographic setting. In summary the study results shows that Prostatype has a strong and significant predictive ability to identify the men that really has a high risk of dying from prostate cancer which is the type of clinical information that doctors and health care payers are looking for. Furthermore, also seen in other published studies, Prostatype significantly outperforms existing clinical prognostic tools adding additional clinical benefit for patients, doctors and health care providers. Notably, no significant difference was observed in the test's performance between African American and Caucasian patients, reinforcing Prostatype's robustness and reliability across different patient groups.お知らせ • May 16Prostatype Genomics AB (Publ) Announces Johan Waldhe Was Not Re-Elects, as He Had Declares That He Was Not Available for Re-ElectionProstatype Genomics AB (publ) at its annual general meeting held on 15 May 2025, approved Johan Waldhe was not re-elected, as he had declared that he was not available for re-election.お知らせ • Apr 16Prostatype Genomics AB (publ), Annual General Meeting, May 15, 2025Prostatype Genomics AB (publ), Annual General Meeting, May 15, 2025, at 15:00 W. Europe Standard Time. Location: at augustendalsvagen 20, 131 52 nacka strand, Swedenお知らせ • Apr 15Prostatype Genomics AB (Publ) Announces Johan Waldhe Not Available for Re-ElectionProstatype Genomics AB (publ) announced that Johan Waldhe has declared that he is not available for re-election due to other commitments.お知らせ • Mar 31Prostatype Genomics Announces Positive Preliminary Results for Primary Endpoints in U.S. Study with ProstatypeProstatype Genomics announced that preliminary results from the study conducted in the United States in collaboration with leading institutions shows promising results. Prostatype is a genomic test designed to improve risk stratification of patients diagnosed with non-metastatic prostate cancer. The study has a diverse patient population, with a significant proportion of African American patients, which is crucial for ensuring the clinical utility of the test in a patient population with multiple ethnicities.お知らせ • Feb 14+ 2 more updatesProstatype Genomics AB (publ) to Report Fiscal Year 2024 Final Results on Apr 24, 2025Prostatype Genomics AB (publ) announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Apr 24, 2025お知らせ • Feb 13Prostatype Genomics AB Submits Supplementary Answers in the Final Phase of its Medicare Application for Reimbursement in the United StatesProstatype Genomics AB announced that the company has compiled and submitted supplementary answers in the final phase of its Medicare application to get the prognostic genomic test Prostatype®? approved for reimbursement in the United States. The compilation has been conducted in an efficient manner together with external partners in Sweden and the United States to create optimal conditions to complete the application process and get Prostatype®? approval for reimbursement in the near future. In the end of September, Prostatype Genomics submitted its application to Medicare (within the MolDX program) to get the genomic test Prostatype®®?, which is used for risk classification of established prostate cancer, approved for reimbursement in the United United States. The application process is facilitated by the fact that the company is applying to include Prostatype®? in an already existing category for reimbursement with an established payment level. On January 3, the company announced that the application had reached its final phase, as a limited number of supplementary questions had been received following Medicare's processing of the full application. These questions were in line with what the company expected, and it has thus been possible to compile the answers in an efficient manner. To make sure that Medicare receives precisely the information requested, as clearly as possible, the company is collaborating with external experts in both Sweden and the United States.お知らせ • Jan 03Prostatype Genomics Medicare Reimbursement Application in the United States Is Now in Its Final PhaseProstatype Genomics AB announced that the company's application for inclusion of the genomic test Prostatype in the federal U.S. healthcare program Medicare's reimbursement system is now in its final phase. A limited number of supplementary questions have been received, and the company is working on compiling the answers which will be submitted to Medicare shortly. The company has thus taken a major step towards completing the application process and getting Prostatype approved for reimbursement in the near future. Prostatype Genomics submitted its application to Medicare (within the MolDX program) according to plan in September 2024. The first supplementary question was received shortly after the application was submitted, but it has taken up until now for the whole application to be processed followed by a more complete response with supplementary questions. The type of supplementary questions received is in line with what the company has been expecting, which means that the answers can be rapidly compiled and sent to Medicare. The company now looks forward to an exciting and value-driving 2025, with a strong focus on commercial activities in the United States, combined with continued commercial activities in selected EMEA markets such as Italy, Spain and Taiwan.Recent Insider Transactions • Sep 28Independent Director recently bought €72k worth of stockOn the 23rd of September, Michael Haggman bought around 41m shares on-market at roughly €0.0018 per share. This transaction increased Michael's direct individual holding by 65x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €69k more in shares than they have sold in the last 12 months.お知らせ • Sep 04Prostatype Genomics AB (publ) has completed a Composite Units Offering in the amount of SEK 39.535402 million.Prostatype Genomics AB (publ) has completed a Composite Units Offering in the amount of SEK 39.535402 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 790,708,046 Price\Range: SEK 0.05 Transaction Features: Rights OfferingReported Earnings • Jul 30First half 2024 earnings released: kr0.031 loss per share (vs kr0.37 loss in 1H 2023)First half 2024 results: kr0.031 loss per share (improved from kr0.37 loss in 1H 2023). Revenue: kr1.45m (up 37% from 1H 2023). Net loss: kr19.7m (loss narrowed 4.3% from 1H 2023).お知らせ • May 24Prostatype Genomics AB (Publ) Elects Johan Waldhe as New Member of the BoardProstatype Genomics AB (publ) at its annual general meeting held on 23 May 2024, Johan Waldhe was elected as new member of the board.お知らせ • Apr 19Prostatype Genomics Announces Very Strong Interim Results from Long-Term Follow-Up Study with Prostatype in UppsalaProstatype Genomics AB announced that interim results from 180 of a total of approximately 500 patients in the ongoing long-term follow-up study at Akademiska University Hospital in Uppsala, Sweden, with the Company's genetic test Prostatype® show excellent accuracy for Prostatype® even after 20 years of follow-up time after diagnosis. None of the analysed patients classified as low risk by Prostatype® died from their prostate cancer during 20 years of follow-up time. The interim results from the Uppsala study, together with data from the ongoing US study with Prostatype® and data from other conducted studies, will be included in the Company's upcoming Medicare application in the United States with the aim to get Prostatype® approved for reimbursement in fourth quarter 2024. Complete interim data from the Uppsala study will be presented at the annual American Urological Association (AUA) conference in the United States in May 2024, one of the leading scientific conferences in the field of urology on a global level. The company's Medicare application to get Prostatype® approved for reimbursement in the United States, with expected submission in Q2-Q3 2024 and expected approval in fourth quarter 2024, will include data from the ongoing US study, as well as data from other studies including the Uppsala study. The United States is the world's largest market for gene testing of patients with established prostate cancer, with current annual sales of approx. SEK 2 billion (USD 200 million), and the Company estimates the total market potential in the United States to be approx. SEK 6 billion (USD 600 million) per year. The genetic test Prostatype® is used as a supplementary guidance for urologists when selecting treatment type for patients diagnosed with prostate cancer. Prostate cancer affects around one in eight men, of which approx. 50-90% undergo radical treatment. According to the Company's assessment, about a third of these radical treatments could be avoided or postponed if the patients were correctly risk-classified, and there is thus a great need for improved guidance when deciding on treatment type.お知らせ • Apr 17+ 1 more updateProstatype Genomics Updates on Significant Progress in the US Study with Prostatype®Prostatype Genomics AB announced that the US study with Prostatype®, which includes approximately 1,200 patients with prostate cancer with a broad ethnicity coverage, is progressing significantly faster than expected. Approximately 40% of the entire study has already been completed. The Company will compile interim data from the study and apply to get Prostatype® approved for reimbursement in the United States by Medicare when approximately 150 African American patients have been analysed. The Company expects to submit the Medicare application in Q2-Q3 2024 and receive approval in Fourth Quarter 2024. Currently, reimbursement from Medicare for genetic testing of patients with diagnosed prostate cancer amounts to approximately USD 3,800 per test. The sales for such gene tests in the US market today amount to approximately SEK 2 billion (SEK 200 million) per year, and the Company estimates that the total market potential in the United States is approximately SEK 6 billion. Due to the high pace in the study, the Company is getting closer and closer to applying for reimbursement from Medicare and receiving an expected approval in Fourth Quarter 2024. The US study is also connected to the ongoing laboratory validation, which constitutes the final regulatory step before the Prostatype® is commercially available in the United States. The laboratory validation is also progressing according to plan, and it is expected to be completed shortly.お知らせ • Feb 16+ 2 more updatesProstatype Genomics AB (publ) to Report First Half, 2024 Results on Aug 22, 2024Prostatype Genomics AB (publ) announced that they will report first half, 2024 results on Aug 22, 2024Reported Earnings • Feb 16Full year 2023 earnings releasedFull year 2023 results: Revenue: kr3.79m (up 455% from FY 2022). Net loss: kr41.4m (loss widened 43% from FY 2022).お知らせ • Dec 22Prostatype Genomics AB (publ) Announces Long Term Follow Up Study At Akademiska University Hospital, Uppsala, to Be Presented At EAU-Meeting, May 2024: Indicates New Area of Use for Prostatype®Prostatype Genomics AB (publ) has in collaboration with Akademiska University Hospital during 2023 initiated a comprehensive study in patients with localized prostate cancer over the course of 25 years. The study has been submitted to the prestigious and largest urology conference in Europe, the 39th Annual EAU (European Association of Urology) Congress. The congress received 5651 abstracts of various kinds, the highest number in many years. The company announced that the new study from Akademiska University Hospital has been selected to present at the EAU Congress in Paris in May, 2024. The interim results, after having analyzed approximately 100 patients out of a total cohort of approximately 500 patients, indicates that the usage of Prostatype® can aid clinicians and patients to make decisions on surveillance versus treatment, rather than having to rely on clinical indicators alone. The results reveals that the test provides an accurate assessment of the risk of long-term prostate cancer-specific mortality, or PCSM, for patients with localized prostate cancer. These 25-year findings suggest that Prostatype® can be used as an indicator of long-term risk of prostate cancer-specific mortality. In the study, researchers at the Akademiska University Hospital analyzes the association between the Prostatype®-result and long-term oncological outcomes following radical prostatectomy in a stratified cohort sample of 500 patients who were treated between 1991 and 2001. The study is expected to be fully completed during the final quarter of 2024. The company is anticipating that the study will be published in a scientific journal later next year which will help to expand the fields of usage of Prostatype® and its recommendation by the American NCCN and the European EAU guidelines for men who've been diagnosed with very low-, low-, or intermediate-risk disease, to determine whether their disease can be conservatively managed through active surveillance rather than treated with definitive surgery or radiation therapy.お知らせ • Nov 07Prostatype Genomics AB (publ) Announces Henrik Nilsson to Leave the Board of Directors PrematurelyProstatype Genomics AB (publ) announced that Henrik Nilsson has announced to the nomination committee that he wish to leave the board of directors prematurely due to family reasons. Therefore, the nomination committee proposes that Henrik Nilsson is replaced by Jörgen Dahlström. At the annual general meeting on 1 June 2023, it was resolved regarding remuneration for the board of directors. No changes are proposed with respect to this resolution. However, the remuneration for the period until the next annual general meeting (2024) will be proportionate to the time Jörgen Dahlström holds the position.Assuming Jörgen Dahlström is elected as member of the board of directors, the Company's board will consist of the following persons: Anders Lundberg (Chairman), Michael Häggman, Mattias Prage, Håkan Englund and Jörgen Dahlström.お知らせ • Nov 01Prostatype Genomics Appoints Anders Koch as New CFOAnders Koch has been appointed as the new CFO for Prostatype Genomics and takes up the position with immediate effect. Anders' extensive experience in streamlining and optimizing operations during growth on an international level will be a great asset for Prostatype Genomics. Anders Koch has over 25 years of experience from positions in finance and leadership, most recently from an interim assignment at Goodbye Kansas Group AB (publ), also listed on Nasdaq First North. Anders Koch succeeds Michael af Winklerfelt, who remains in the company during a handover period.お知らせ • Oct 31Prostatype Genomics AB (Publ) Announces Updated Strategy and Implementation of Efficiency Programs in Prostatype GenomicsProstatype Genomics AB announced that during 2022 and 2023, Prostatype Genomics has introduced Prostatype®?, the company's prognostic gene test for prostate cancer, in European pilot markets and in Taiwan in parallel with a mapping of the market in the USA. Based on these experiences, the company can now specify the strategy moving forward which means: that the company continues to invest in attractive entry countries within Europe; that the company expands the business in Asia with Taiwan as a springboard; that the company implements a quick and cost-effective establishment in the American market. This will be achieved at the same time as an efficiency program is implemented, which means that running costs are reduced by approximately 30% (approximately SEK 9 million on an annual basis) without affecting sales and continued research. Prostatype Genomics has two main strategic areas of activity: commercial establishment and strengthening of Prostatype®?'s scientific basis in the form of external studies. Over the past two years, the company has systematically worked to map and evaluate various markets and approaches from a commercial perspective on site in various countries in order to identify whether the following criteria are met or can be met in the near future: Clinical acceptance of genetic testing in prostate cancer and confirmed clinical benefit; Market acceptance via clinics evaluating and starting to use Prostatype®? on a smaller scale. It is difficult to predict how a patient's prostate cancer should best be treated with conventional methods. The company have been able to establish that the clinical need for accurate biomarkers in diagnosed prostate cancer is very clear regardless of European country. The company has managed to achieve a high trial rate in clinics with strong results and the doctors are positive, which has shown that Prostatype®? fulfils a large and clear clinical need. Prostatype®? will be launched on the American market as a so-called LDT product (Laboratory Developed Test). The company thereby avoid a long, costly and uncertain FDA process. The company do not differ from American companies that provide similar products but use the same established approach. Furthermore, do not establish own laboratory in the USA but work with a "lab-in-lab" solution where the company uses an already existing infrastructure of a partner who holds the necessary permits and a so-called CLIA license. This ensures high flexibility for extensive sales in the US in a cost-effective manner. The US market for product is estimated to be worth approximately 600 MUSD annually. With a completed study in the USA, goal is for the product to achieve the attractiveness required to be able to switch up the business after Fourth Quarter 2024 via partnerships with major players in the industry on a global or regional basis either in the form of part ownership or commercial collaboration. This work has already started. As already mentioned, the company, based on the experiences gained during 2022 and 2023, has introduced an efficiency program. This program will lead to an annual reduction of current costs corresponding to SEK 9 million or approximately 30% of the total cost. The board's and management's joint assessment is that this can be implemented without the overall strategy or pace being affected, as resources are instead concentrated on the markets where the company see immediate potential. Work on continuous product development can continue at an unchanged level. Streamlining further frees up the resources needed for the company's primary focus, which is the American market.お知らせ • Oct 26Prostatype Genomics Announces New Multi-Centre Study in Spain Shows Very Strong Interim Results for Prostatype(R)Prostatype Genomics is currently conducting a study of 160 patients together with seven leading Spanish hospitals and the Spanish National Association of Urology. The initial results are very strong and show that approximately 60% of patients would have been reclassified if Prostatype had been used for prognostic and treatment decisions after diagnosis. In a new retrospective multicentre study with Prostatype(R) in Spain including 160 patients from a total of seven hospitals, coordinated by the Spanish National association of Urology, an interim analysis has been performed after three hospitals completed the results. The interim analysis shows that there is again strong evidence that Prostatype(R) provides important additional information that can change the treatment plan or actual treatment for prostate cancer patients initially classified as low or intermediate risk. The initial analysis indicates that the treatment plan can be changed in approximately as many as 60% of the cases if Prostatype(R) had been used after the established diagnosis. The study further indicates that Prostatype(R") can predict progression, i.e., the test can predict who needs curative treatment immediately upon diagnosis and who are not suitable for active monitoring. The interim analysis also shows that Prostatype(R), confirms the cases in which it may be appropriate to postpone curative treatment for some men with low-risk prostate cancer. In conclusion, the analysis shows that the patients who develop metastases and die due to prostate cancer are classified as high risk with Prostatype(R). at the time of diagnosis.Breakeven Date Change • Oct 19Forecast to breakeven in 2025The analyst covering Prostatype Genomics expects the company to break even for the first time. New forecast suggests the company will make a profit of kr7.00m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule.お知らせ • Sep 05Prostatype Genomics CFO Michael af Winklerfelt Leaving the CompanyProstatype Genomics CFO Michael af Winklerfelt is leaving the company after three years. Michael will resign from his position as of December 4. The company has started the process of finding a replacement for the function as CFO.Breakeven Date Change • Sep 01Forecast to breakeven in 2025The analyst covering Prostatype Genomics expects the company to break even for the first time. New forecast suggests the company will make a profit of kr7.00m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule.Reported Earnings • Aug 18Second quarter 2023 earnings releasedSecond quarter 2023 results: Net loss: kr10.1m (loss widened 37% from 2Q 2022). Revenue is forecast to grow 114% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.お知らせ • Aug 18Prostatype Genomics AB (Publ) Provides Revenue Guidance for the Third Quarter of 2023Prostatype Genomics AB (publ) provided revenue guidance for the third quarter of 2023. The Company also projects that revenue growth will return to positive trend in the Third Quarter.Buying Opportunity • Jul 13Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be €0.038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 2,779% in 2 years. Earnings is forecast to grow by 36% in the next 2 years.お知らせ • Jun 21Prostatype Genomics AB Appoints Gerald Andriole as Chief Medical OfficerProstatype Genomics AB announced that Professor Gerald Andriole has been appointed as global Chief Medical Officer at Prostatype Genomics. With more than 35 years in urology, Professor Andriole brings a wealth of experience and expertise to Prostatype Genomics as the company works towards commercializing the Prostatype® test in the United States and globally. Gerald L. Andriole, Jr., MD, was most recently Professor in the Department of Urology and Director of the Brady Urological Institute in the National Capital Region of Johns Hopkins University. Previously, he was the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine in St. Louis, Missouri. Professor Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He completed urology residency at Brigham and Women's Hospital and Harvard Medical School, Boston, MA. He then received specialty training in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland. Professor Andriole has over 35 years of consistent contributions in caring for men with prostate cancer and in prostate cancer prevention, screening and treatment research. He has contributed more than 450 peer-reviewed publications and has served on the editorial boards of several prestigious medical journals. He has been Chairman of the Prostate Committee of the National Cancer Institute's Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial; Chairman of the Prostate Committee for the Society of Urologic Oncology Clinical Trials Consortium; and Chairman of the Steering Committee of the REDUCE International Prostate Cancer Prevention Trial. Professor Andriole has been the recipient of numerous awards including the outstanding achievement award from the Urologic Oncology Branch of the National Cancer Institute, the Distinguished Clinician Award from Washington University in St. Louis and the Richard Williams Award for Prostate Cancer Research Excellence from the American Urologic Association Urology Care Foundation.Reported Earnings • Jun 02First quarter 2023 earnings releasedFirst quarter 2023 results: Net loss: kr7.81m (loss widened 41% from 1Q 2022).お知らせ • Jun 02+ 1 more updateProstatype Genomics AB (Publ) Announces Executive ChangesProstatype Genomics AB (publ) announced executive changes. The company announced election of Henrik Nilsson as new member of the board and Karlheinz Schmelig was not available for re-election.お知らせ • May 13Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 17.787846 million.Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 17.787846 million. Security Name: Shares Security Type: Common Stock Securities Offered: 71,151,384 Price\Range: SEK 0.25 Transaction Features: Rights Offeringお知らせ • May 06Prostatype Genomics AB Appoints Professor Gerald Andriole as Chief Medical OfficerProstatype Genomics AB announced that Professor Gerald Andriole has been appointed as global Chief Medical Officer at Prostatype Genomics. With more than 35 years in urology, Professor Andriole brings a wealth of experience and expertise to Prostatype Genomics as the company works towards commercializing the Prostatype® test in the United States and globally. Gerald L. Andriole, Jr., MD, was most recently Professor in the Department of Urology and Director of the Brady Urological Institute in the National Capital Region of Johns Hopkins University. Previously, he was the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine in St. Louis, Missouri. Professor Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He completed urology residency at Brigham and Women's Hospital and Harvard Medical School, Boston, MA. He then received specialty training in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland. Professor Andriole has over 35 years of consistent contributions in caring for men with prostate cancer and in prostate cancer prevention, screening and treatment research. He has contributed more than 450 peer-reviewed publications and has served on the editorial boards of several prestigious medical journals. He has been Chairman of the Prostate Committee of the National Cancer Institute's Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial; Chairman of the Prostate Committee for the Society of Urologic Oncology Clinical Trials Consortium; and Chairman of the Steering Committee of the REDUCE International Prostate Cancer Prevention Trial.Reported Earnings • Feb 18Full year 2022 earnings released: kr1.27 loss per share (vs kr1.11 loss in FY 2021)Full year 2022 results: kr1.27 loss per share (further deteriorated from kr1.11 loss in FY 2021). Net loss: kr29.1m (loss widened 86% from FY 2021).お知らせ • Feb 17Prostatype Genomics AB (publ) to Report Fiscal Year 2022 Results on May 04, 2023Prostatype Genomics AB (publ) announced that they will report fiscal year 2022 results on May 04, 2023お知らせ • Feb 16+ 4 more updatesProstatype Genomics AB (publ) to Report Q2, 2023 Results on Aug 17, 2023Prostatype Genomics AB (publ) announced that they will report Q2, 2023 results on Aug 17, 2023お知らせ • Jan 12Prostatype Genomics Appoints Steven Gaal as PresidentProstatype Genomics AB (publ) has recruited Steven Gaal to the role of President of the company's wholly owned subsidiary, Prostatype Genomics Inc. Steven's task will be to establish and launch Prostatype®, the company's genomic test to assess the aggressiveness of prostate cancer in individual patients, in the US market. Steven has over 18 years of experience from leading positions in the sale of cancer diagnostic tools and services and begins his employment with Prostatype Genomics Inc. effective immediately. Steven comes to Prostatype Genomics Inc. with extensive experience in genomic testing. Steven has held positions in both early stage companies as well as established companies. He has held senior leadership positions with USLABS (acquired by LabCorp), P4Diagnostix and most recently SkylineDx. As VP of Sales at MDxHealth Steven was instrumental in the launch of ConfirmMDx for Prostate Cancer and SelectMDx for Prostate Cancer to US based Urologists.お知らせ • Nov 08Prostatype Genomics AB (Publ) Provides Sales Guidance for the Year 2022Prostatype Genomics AB (publ) provided sales guidance for the year 2022. Sales in 2022 are estimated to amount to SEK 700,000.お知らせ • Oct 19Prostatype Genomics Announces Management ChangesOn November 8, 2022 Emelie will take over the important role of CTO of Prostatype Genomics from Lidi Xu, who has held the position since 2019. Lidi is leaving the company to move back to China with her family but will continue to work on various projects for Prostatype Genomics. Emelie Berglund has a PhD in Biotechnology from the Royal Institute of Technology in Stockholm, and more than seven years of combined research experience within prostate cancer. After her degree, Emelie has led the R&D operations of a Swedish life science company that develops products in cancer detection and biomarker analysis. Emelie's main tasks will be to strengthen the scientific footprint of Prostatype Genomics by initiating, running, and coordinating validation studies around the world, ensuring that the results are published in the right channels and working with product development of the Prostatype® Test System, the company's product for prognosticating the aggressiveness of a prostate cancer. Emelie's focus areas are in line with previously communicated objectives from Prostatype Genomics. Emelie will also work in close collaboration with the commercial part of the company as there is great interest in Prostatype® in all priority markets. The company is currently in advanced discussions with leading urologists who have already used and evaluated Prostatype® and is on its way to a more routine use of the product. The increased use of Prostatype® has led to a significant influx of further contacts with customers, where Emelie's skills and experience will ensure that the company continue to deliver a continued good service also in terms of the scientific discussions.お知らせ • Sep 16Prostatype Shows Strong Data in Asian Pilot StudyWith the second independent pilot study in the East Asia region showing strong clinical performance, Prostatype Genomics is now reviewing commercialization opportunities in the region. The recent study was conducted in China in collaboration with the Nanjing Drum Tower University Hospital, Jiangsu, and Prostatype Genomics' partner GloriousMed based in Shanghai. The study indicates that the clinical performance of Prostatype® in East Asian population is in line with the results previously communicated results in several studies in Caucasian populations. Strong predictive performance: In total 108 patients were included in the pilot study. All patients who either died from prostate cancer or developed metastasis were identified as "high-risk patients" according to the Prostatype® risk score (P-score) algorithm. The algorithm developed by Prostatype Genomics where the patients genetic information from genes closest associated with aggressive prostate cancer is added together with other relevant clinical parameters to form the P-score. In addition, more than 26% of the patients (28 patients in total) were downgraded from a higher risk group to a lower risk group which is clinically important as it often results in different treatment options. The median follow-up time was 5.3 years from diagnosis. finalized two independent pilot studies in the East Asia region showing robust clinical performance by Prostatype. Based on the previous strong results from the ongoing more comprehensive validation study in Taiwan, the company are encouraged by the opportunities these results give Prostatype Genomics in the large and commercially interesting market of East Asia. Company are currently reviewing the specific commercialization opportunities in the region. The ongoing challenges with Covid-19 in China and other countries in East Asia, including difficulties to travel due to Covid-restrictions, will decide how quickly company will be able to move forward in this specific market. The results of the study will be presented at the Chinese Urology Association's national congress on September 21-25, by Dr. Zhang Shun from the Nanjing Drum Tower Hospital.Reported Earnings • Aug 19Second quarter 2022 earnings releasedSecond quarter 2022 results: Net loss: kr7.39m (loss widened 213% from 2Q 2021). Over the next year, revenue is forecast to grow 1,278%, compared to a 11% growth forecast for the Biotechs industry in Germany.Board Change • Jul 31High number of new directorsDirector Mattias Prage was the last director to join the board, commencing their role in 2022.お知らせ • Jun 03Prostatype Genomics AB (Publ) Appoints Mattias Prage as Member of the BoardProstatype Genomics AB (publ) at its annual general meeting held on June 2, 2022, Mattias Prage was elected as new member of the board.Reported Earnings • May 14First quarter 2022 earnings releasedFirst quarter 2022 results: Net loss: kr5.56m (loss widened 62% from 1Q 2021). Over the next year, revenue is forecast to grow 603%, compared to a 36% growth forecast for the industry in Germany.Board Change • May 12Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Hakan Englund was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Feb 25+ 5 more updatesProstatype Genomics AB (publ) to Report Q3, 2022 Results on Nov 10, 2022Prostatype Genomics AB (publ) announced that they will report Q3, 2022 results on Nov 10, 2022Board Change • Feb 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Hakan Englund was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 19Third quarter 2021 earnings releasedThird quarter 2021 results: Net loss: kr3.66m (loss narrowed 23% from 3Q 2020).お知らせ • Aug 28Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 24.724583 million.Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 24.724583 million. Security Name: Shares Security Type: Common Stock Securities Offered: 1,901,891 Price\Range: SEK 13 Transaction Features: Subsequent Direct ListingReported Earnings • Aug 21Second quarter 2021 earnings released: kr0.18 loss per share (vs kr0.42 loss in 2Q 2020)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: kr549.0k (down 50% from 2Q 2020). Net loss: kr2.36m (loss narrowed 51% from 2Q 2020).株主還元PGO0DE BiotechsDE 市場7D-44.1%1.8%2.4%1Y-68.6%-12.5%1.2%株主還元を見る業界別リターン: PGO0過去 1 年間で-12.5 % の収益を上げたGerman Biotechs業界を下回りました。リターン対市場: PGO0は、過去 1 年間で1.2 % のリターンを上げたGerman市場を下回りました。価格変動Is PGO0's price volatile compared to industry and market?PGO0 volatilityPGO0 Average Weekly Movement35.2%Biotechs Industry Average Movement8.5%Market Average Movement6.1%10% most volatile stocks in DE Market13.4%10% least volatile stocks in DE Market2.7%安定した株価: PGO0の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: PGO0の weekly volatility ( 35% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20076Fredrik Rickmanwww.prostatypegenomics.comProstatype Genomics ABは予後遺伝子検査の製造、販売、マーケティングを行っている。PSA、グリソンスコア、腫瘍ステージなどの臨床パラメータと遺伝子発現情報を組み合わせ、Pスコアを算出するProstatype検査システムを提供している。同社の検査は、前立腺がん患者を含むデータベースに基づいており、患者や医師が治療を決定する際の意思決定をサポートする。Prostatype Genomics AB（publ）は2007年に設立され、スウェーデンのソルナに本社を置いている。もっと見るProstatype Genomics AB (publ) 基礎のまとめProstatype Genomics の収益と売上を時価総額と比較するとどうか。PGO0 基礎統計学時価総額€2.07m収益（TTM）-€4.10m売上高(TTM)€54.69k37.9xP/Sレシオ-0.5xPER（株価収益率PGO0 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PGO0 損益計算書（TTM）収益SEK 594.00k売上原価SEK 20.80m売上総利益-SEK 20.20mその他の費用SEK 24.30m収益-SEK 44.50m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.75グロス・マージン-3,401.35%純利益率-7,492.09%有利子負債／自己資本比率0%PGO0 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 20:02終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Prostatype Genomics AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Johan UnnerusRedeye
お知らせ • May 21Prostatype Genomics AB (publ), Annual General Meeting, Jun 22, 2026Prostatype Genomics AB (publ), Annual General Meeting, Jun 22, 2026, at 15:00 W. Europe Standard Time. Location: augustendalsvagen 20, nacka strand, Sweden
お知らせ • Jan 09Prostatype Genomics U.S. Validation Study by Veterans Affairs (Va) Is PublishedProstatype Genomics announced that the study performed in USA under the leadership of professor Stephen Freedland at Department of Urology at Cedars-Sinai, and in association with the Durham Veteran Affairs Healthcare System, has been accepted and is published in the medical journal Prostate Cancer and Prostatic Diseases Veterans Affairs is one of the world's largest integrated health care systems where Cedars-Sinai is ranked among the top 10 most influential hospitals in USA. The study includes a diverse patient population, with a significant proportion of African American patients, which is crucial for ensuring the clinical utility of the test across a broad demographic setting. In summary the study results shows that Prostatype has a strong and significant predictive ability to identify the men that really has a high risk of dying from prostate cancer which is the type of clinical information that doctors and health care payers are looking for. Furthermore, also seen in other published studies, Prostatype significantly outperforms existing clinical prognostic tools adding additional clinical benefit for patients, doctors and health care providers. Notably, no significant difference was observed in the test's performance between African American and Caucasian patients, reinforcing Prostatype's robustness and reliability across different patient groups.
お知らせ • May 16Prostatype Genomics AB (Publ) Announces Johan Waldhe Was Not Re-Elects, as He Had Declares That He Was Not Available for Re-ElectionProstatype Genomics AB (publ) at its annual general meeting held on 15 May 2025, approved Johan Waldhe was not re-elected, as he had declared that he was not available for re-election.
お知らせ • Apr 16Prostatype Genomics AB (publ), Annual General Meeting, May 15, 2025Prostatype Genomics AB (publ), Annual General Meeting, May 15, 2025, at 15:00 W. Europe Standard Time. Location: at augustendalsvagen 20, 131 52 nacka strand, Sweden
お知らせ • Apr 15Prostatype Genomics AB (Publ) Announces Johan Waldhe Not Available for Re-ElectionProstatype Genomics AB (publ) announced that Johan Waldhe has declared that he is not available for re-election due to other commitments.
お知らせ • Mar 31Prostatype Genomics Announces Positive Preliminary Results for Primary Endpoints in U.S. Study with ProstatypeProstatype Genomics announced that preliminary results from the study conducted in the United States in collaboration with leading institutions shows promising results. Prostatype is a genomic test designed to improve risk stratification of patients diagnosed with non-metastatic prostate cancer. The study has a diverse patient population, with a significant proportion of African American patients, which is crucial for ensuring the clinical utility of the test in a patient population with multiple ethnicities.
お知らせ • May 21Prostatype Genomics AB (publ), Annual General Meeting, Jun 22, 2026Prostatype Genomics AB (publ), Annual General Meeting, Jun 22, 2026, at 15:00 W. Europe Standard Time. Location: augustendalsvagen 20, nacka strand, Sweden
お知らせ • Jan 09Prostatype Genomics U.S. Validation Study by Veterans Affairs (Va) Is PublishedProstatype Genomics announced that the study performed in USA under the leadership of professor Stephen Freedland at Department of Urology at Cedars-Sinai, and in association with the Durham Veteran Affairs Healthcare System, has been accepted and is published in the medical journal Prostate Cancer and Prostatic Diseases Veterans Affairs is one of the world's largest integrated health care systems where Cedars-Sinai is ranked among the top 10 most influential hospitals in USA. The study includes a diverse patient population, with a significant proportion of African American patients, which is crucial for ensuring the clinical utility of the test across a broad demographic setting. In summary the study results shows that Prostatype has a strong and significant predictive ability to identify the men that really has a high risk of dying from prostate cancer which is the type of clinical information that doctors and health care payers are looking for. Furthermore, also seen in other published studies, Prostatype significantly outperforms existing clinical prognostic tools adding additional clinical benefit for patients, doctors and health care providers. Notably, no significant difference was observed in the test's performance between African American and Caucasian patients, reinforcing Prostatype's robustness and reliability across different patient groups.
お知らせ • May 16Prostatype Genomics AB (Publ) Announces Johan Waldhe Was Not Re-Elects, as He Had Declares That He Was Not Available for Re-ElectionProstatype Genomics AB (publ) at its annual general meeting held on 15 May 2025, approved Johan Waldhe was not re-elected, as he had declared that he was not available for re-election.
お知らせ • Apr 16Prostatype Genomics AB (publ), Annual General Meeting, May 15, 2025Prostatype Genomics AB (publ), Annual General Meeting, May 15, 2025, at 15:00 W. Europe Standard Time. Location: at augustendalsvagen 20, 131 52 nacka strand, Sweden
お知らせ • Apr 15Prostatype Genomics AB (Publ) Announces Johan Waldhe Not Available for Re-ElectionProstatype Genomics AB (publ) announced that Johan Waldhe has declared that he is not available for re-election due to other commitments.
お知らせ • Mar 31Prostatype Genomics Announces Positive Preliminary Results for Primary Endpoints in U.S. Study with ProstatypeProstatype Genomics announced that preliminary results from the study conducted in the United States in collaboration with leading institutions shows promising results. Prostatype is a genomic test designed to improve risk stratification of patients diagnosed with non-metastatic prostate cancer. The study has a diverse patient population, with a significant proportion of African American patients, which is crucial for ensuring the clinical utility of the test in a patient population with multiple ethnicities.
お知らせ • Feb 14+ 2 more updatesProstatype Genomics AB (publ) to Report Fiscal Year 2024 Final Results on Apr 24, 2025Prostatype Genomics AB (publ) announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Apr 24, 2025
お知らせ • Feb 13Prostatype Genomics AB Submits Supplementary Answers in the Final Phase of its Medicare Application for Reimbursement in the United StatesProstatype Genomics AB announced that the company has compiled and submitted supplementary answers in the final phase of its Medicare application to get the prognostic genomic test Prostatype®? approved for reimbursement in the United States. The compilation has been conducted in an efficient manner together with external partners in Sweden and the United States to create optimal conditions to complete the application process and get Prostatype®? approval for reimbursement in the near future. In the end of September, Prostatype Genomics submitted its application to Medicare (within the MolDX program) to get the genomic test Prostatype®®?, which is used for risk classification of established prostate cancer, approved for reimbursement in the United United States. The application process is facilitated by the fact that the company is applying to include Prostatype®? in an already existing category for reimbursement with an established payment level. On January 3, the company announced that the application had reached its final phase, as a limited number of supplementary questions had been received following Medicare's processing of the full application. These questions were in line with what the company expected, and it has thus been possible to compile the answers in an efficient manner. To make sure that Medicare receives precisely the information requested, as clearly as possible, the company is collaborating with external experts in both Sweden and the United States.
お知らせ • Jan 03Prostatype Genomics Medicare Reimbursement Application in the United States Is Now in Its Final PhaseProstatype Genomics AB announced that the company's application for inclusion of the genomic test Prostatype in the federal U.S. healthcare program Medicare's reimbursement system is now in its final phase. A limited number of supplementary questions have been received, and the company is working on compiling the answers which will be submitted to Medicare shortly. The company has thus taken a major step towards completing the application process and getting Prostatype approved for reimbursement in the near future. Prostatype Genomics submitted its application to Medicare (within the MolDX program) according to plan in September 2024. The first supplementary question was received shortly after the application was submitted, but it has taken up until now for the whole application to be processed followed by a more complete response with supplementary questions. The type of supplementary questions received is in line with what the company has been expecting, which means that the answers can be rapidly compiled and sent to Medicare. The company now looks forward to an exciting and value-driving 2025, with a strong focus on commercial activities in the United States, combined with continued commercial activities in selected EMEA markets such as Italy, Spain and Taiwan.
Recent Insider Transactions • Sep 28Independent Director recently bought €72k worth of stockOn the 23rd of September, Michael Haggman bought around 41m shares on-market at roughly €0.0018 per share. This transaction increased Michael's direct individual holding by 65x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €69k more in shares than they have sold in the last 12 months.
お知らせ • Sep 04Prostatype Genomics AB (publ) has completed a Composite Units Offering in the amount of SEK 39.535402 million.Prostatype Genomics AB (publ) has completed a Composite Units Offering in the amount of SEK 39.535402 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 790,708,046 Price\Range: SEK 0.05 Transaction Features: Rights Offering
Reported Earnings • Jul 30First half 2024 earnings released: kr0.031 loss per share (vs kr0.37 loss in 1H 2023)First half 2024 results: kr0.031 loss per share (improved from kr0.37 loss in 1H 2023). Revenue: kr1.45m (up 37% from 1H 2023). Net loss: kr19.7m (loss narrowed 4.3% from 1H 2023).
お知らせ • May 24Prostatype Genomics AB (Publ) Elects Johan Waldhe as New Member of the BoardProstatype Genomics AB (publ) at its annual general meeting held on 23 May 2024, Johan Waldhe was elected as new member of the board.
お知らせ • Apr 19Prostatype Genomics Announces Very Strong Interim Results from Long-Term Follow-Up Study with Prostatype in UppsalaProstatype Genomics AB announced that interim results from 180 of a total of approximately 500 patients in the ongoing long-term follow-up study at Akademiska University Hospital in Uppsala, Sweden, with the Company's genetic test Prostatype® show excellent accuracy for Prostatype® even after 20 years of follow-up time after diagnosis. None of the analysed patients classified as low risk by Prostatype® died from their prostate cancer during 20 years of follow-up time. The interim results from the Uppsala study, together with data from the ongoing US study with Prostatype® and data from other conducted studies, will be included in the Company's upcoming Medicare application in the United States with the aim to get Prostatype® approved for reimbursement in fourth quarter 2024. Complete interim data from the Uppsala study will be presented at the annual American Urological Association (AUA) conference in the United States in May 2024, one of the leading scientific conferences in the field of urology on a global level. The company's Medicare application to get Prostatype® approved for reimbursement in the United States, with expected submission in Q2-Q3 2024 and expected approval in fourth quarter 2024, will include data from the ongoing US study, as well as data from other studies including the Uppsala study. The United States is the world's largest market for gene testing of patients with established prostate cancer, with current annual sales of approx. SEK 2 billion (USD 200 million), and the Company estimates the total market potential in the United States to be approx. SEK 6 billion (USD 600 million) per year. The genetic test Prostatype® is used as a supplementary guidance for urologists when selecting treatment type for patients diagnosed with prostate cancer. Prostate cancer affects around one in eight men, of which approx. 50-90% undergo radical treatment. According to the Company's assessment, about a third of these radical treatments could be avoided or postponed if the patients were correctly risk-classified, and there is thus a great need for improved guidance when deciding on treatment type.
お知らせ • Apr 17+ 1 more updateProstatype Genomics Updates on Significant Progress in the US Study with Prostatype®Prostatype Genomics AB announced that the US study with Prostatype®, which includes approximately 1,200 patients with prostate cancer with a broad ethnicity coverage, is progressing significantly faster than expected. Approximately 40% of the entire study has already been completed. The Company will compile interim data from the study and apply to get Prostatype® approved for reimbursement in the United States by Medicare when approximately 150 African American patients have been analysed. The Company expects to submit the Medicare application in Q2-Q3 2024 and receive approval in Fourth Quarter 2024. Currently, reimbursement from Medicare for genetic testing of patients with diagnosed prostate cancer amounts to approximately USD 3,800 per test. The sales for such gene tests in the US market today amount to approximately SEK 2 billion (SEK 200 million) per year, and the Company estimates that the total market potential in the United States is approximately SEK 6 billion. Due to the high pace in the study, the Company is getting closer and closer to applying for reimbursement from Medicare and receiving an expected approval in Fourth Quarter 2024. The US study is also connected to the ongoing laboratory validation, which constitutes the final regulatory step before the Prostatype® is commercially available in the United States. The laboratory validation is also progressing according to plan, and it is expected to be completed shortly.
お知らせ • Feb 16+ 2 more updatesProstatype Genomics AB (publ) to Report First Half, 2024 Results on Aug 22, 2024Prostatype Genomics AB (publ) announced that they will report first half, 2024 results on Aug 22, 2024
Reported Earnings • Feb 16Full year 2023 earnings releasedFull year 2023 results: Revenue: kr3.79m (up 455% from FY 2022). Net loss: kr41.4m (loss widened 43% from FY 2022).
お知らせ • Dec 22Prostatype Genomics AB (publ) Announces Long Term Follow Up Study At Akademiska University Hospital, Uppsala, to Be Presented At EAU-Meeting, May 2024: Indicates New Area of Use for Prostatype®Prostatype Genomics AB (publ) has in collaboration with Akademiska University Hospital during 2023 initiated a comprehensive study in patients with localized prostate cancer over the course of 25 years. The study has been submitted to the prestigious and largest urology conference in Europe, the 39th Annual EAU (European Association of Urology) Congress. The congress received 5651 abstracts of various kinds, the highest number in many years. The company announced that the new study from Akademiska University Hospital has been selected to present at the EAU Congress in Paris in May, 2024. The interim results, after having analyzed approximately 100 patients out of a total cohort of approximately 500 patients, indicates that the usage of Prostatype® can aid clinicians and patients to make decisions on surveillance versus treatment, rather than having to rely on clinical indicators alone. The results reveals that the test provides an accurate assessment of the risk of long-term prostate cancer-specific mortality, or PCSM, for patients with localized prostate cancer. These 25-year findings suggest that Prostatype® can be used as an indicator of long-term risk of prostate cancer-specific mortality. In the study, researchers at the Akademiska University Hospital analyzes the association between the Prostatype®-result and long-term oncological outcomes following radical prostatectomy in a stratified cohort sample of 500 patients who were treated between 1991 and 2001. The study is expected to be fully completed during the final quarter of 2024. The company is anticipating that the study will be published in a scientific journal later next year which will help to expand the fields of usage of Prostatype® and its recommendation by the American NCCN and the European EAU guidelines for men who've been diagnosed with very low-, low-, or intermediate-risk disease, to determine whether their disease can be conservatively managed through active surveillance rather than treated with definitive surgery or radiation therapy.
お知らせ • Nov 07Prostatype Genomics AB (publ) Announces Henrik Nilsson to Leave the Board of Directors PrematurelyProstatype Genomics AB (publ) announced that Henrik Nilsson has announced to the nomination committee that he wish to leave the board of directors prematurely due to family reasons. Therefore, the nomination committee proposes that Henrik Nilsson is replaced by Jörgen Dahlström. At the annual general meeting on 1 June 2023, it was resolved regarding remuneration for the board of directors. No changes are proposed with respect to this resolution. However, the remuneration for the period until the next annual general meeting (2024) will be proportionate to the time Jörgen Dahlström holds the position.Assuming Jörgen Dahlström is elected as member of the board of directors, the Company's board will consist of the following persons: Anders Lundberg (Chairman), Michael Häggman, Mattias Prage, Håkan Englund and Jörgen Dahlström.
お知らせ • Nov 01Prostatype Genomics Appoints Anders Koch as New CFOAnders Koch has been appointed as the new CFO for Prostatype Genomics and takes up the position with immediate effect. Anders' extensive experience in streamlining and optimizing operations during growth on an international level will be a great asset for Prostatype Genomics. Anders Koch has over 25 years of experience from positions in finance and leadership, most recently from an interim assignment at Goodbye Kansas Group AB (publ), also listed on Nasdaq First North. Anders Koch succeeds Michael af Winklerfelt, who remains in the company during a handover period.
お知らせ • Oct 31Prostatype Genomics AB (Publ) Announces Updated Strategy and Implementation of Efficiency Programs in Prostatype GenomicsProstatype Genomics AB announced that during 2022 and 2023, Prostatype Genomics has introduced Prostatype®?, the company's prognostic gene test for prostate cancer, in European pilot markets and in Taiwan in parallel with a mapping of the market in the USA. Based on these experiences, the company can now specify the strategy moving forward which means: that the company continues to invest in attractive entry countries within Europe; that the company expands the business in Asia with Taiwan as a springboard; that the company implements a quick and cost-effective establishment in the American market. This will be achieved at the same time as an efficiency program is implemented, which means that running costs are reduced by approximately 30% (approximately SEK 9 million on an annual basis) without affecting sales and continued research. Prostatype Genomics has two main strategic areas of activity: commercial establishment and strengthening of Prostatype®?'s scientific basis in the form of external studies. Over the past two years, the company has systematically worked to map and evaluate various markets and approaches from a commercial perspective on site in various countries in order to identify whether the following criteria are met or can be met in the near future: Clinical acceptance of genetic testing in prostate cancer and confirmed clinical benefit; Market acceptance via clinics evaluating and starting to use Prostatype®? on a smaller scale. It is difficult to predict how a patient's prostate cancer should best be treated with conventional methods. The company have been able to establish that the clinical need for accurate biomarkers in diagnosed prostate cancer is very clear regardless of European country. The company has managed to achieve a high trial rate in clinics with strong results and the doctors are positive, which has shown that Prostatype®? fulfils a large and clear clinical need. Prostatype®? will be launched on the American market as a so-called LDT product (Laboratory Developed Test). The company thereby avoid a long, costly and uncertain FDA process. The company do not differ from American companies that provide similar products but use the same established approach. Furthermore, do not establish own laboratory in the USA but work with a "lab-in-lab" solution where the company uses an already existing infrastructure of a partner who holds the necessary permits and a so-called CLIA license. This ensures high flexibility for extensive sales in the US in a cost-effective manner. The US market for product is estimated to be worth approximately 600 MUSD annually. With a completed study in the USA, goal is for the product to achieve the attractiveness required to be able to switch up the business after Fourth Quarter 2024 via partnerships with major players in the industry on a global or regional basis either in the form of part ownership or commercial collaboration. This work has already started. As already mentioned, the company, based on the experiences gained during 2022 and 2023, has introduced an efficiency program. This program will lead to an annual reduction of current costs corresponding to SEK 9 million or approximately 30% of the total cost. The board's and management's joint assessment is that this can be implemented without the overall strategy or pace being affected, as resources are instead concentrated on the markets where the company see immediate potential. Work on continuous product development can continue at an unchanged level. Streamlining further frees up the resources needed for the company's primary focus, which is the American market.
お知らせ • Oct 26Prostatype Genomics Announces New Multi-Centre Study in Spain Shows Very Strong Interim Results for Prostatype(R)Prostatype Genomics is currently conducting a study of 160 patients together with seven leading Spanish hospitals and the Spanish National Association of Urology. The initial results are very strong and show that approximately 60% of patients would have been reclassified if Prostatype had been used for prognostic and treatment decisions after diagnosis. In a new retrospective multicentre study with Prostatype(R) in Spain including 160 patients from a total of seven hospitals, coordinated by the Spanish National association of Urology, an interim analysis has been performed after three hospitals completed the results. The interim analysis shows that there is again strong evidence that Prostatype(R) provides important additional information that can change the treatment plan or actual treatment for prostate cancer patients initially classified as low or intermediate risk. The initial analysis indicates that the treatment plan can be changed in approximately as many as 60% of the cases if Prostatype(R) had been used after the established diagnosis. The study further indicates that Prostatype(R") can predict progression, i.e., the test can predict who needs curative treatment immediately upon diagnosis and who are not suitable for active monitoring. The interim analysis also shows that Prostatype(R), confirms the cases in which it may be appropriate to postpone curative treatment for some men with low-risk prostate cancer. In conclusion, the analysis shows that the patients who develop metastases and die due to prostate cancer are classified as high risk with Prostatype(R). at the time of diagnosis.
Breakeven Date Change • Oct 19Forecast to breakeven in 2025The analyst covering Prostatype Genomics expects the company to break even for the first time. New forecast suggests the company will make a profit of kr7.00m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule.
お知らせ • Sep 05Prostatype Genomics CFO Michael af Winklerfelt Leaving the CompanyProstatype Genomics CFO Michael af Winklerfelt is leaving the company after three years. Michael will resign from his position as of December 4. The company has started the process of finding a replacement for the function as CFO.
Breakeven Date Change • Sep 01Forecast to breakeven in 2025The analyst covering Prostatype Genomics expects the company to break even for the first time. New forecast suggests the company will make a profit of kr7.00m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule.
Reported Earnings • Aug 18Second quarter 2023 earnings releasedSecond quarter 2023 results: Net loss: kr10.1m (loss widened 37% from 2Q 2022). Revenue is forecast to grow 114% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.
お知らせ • Aug 18Prostatype Genomics AB (Publ) Provides Revenue Guidance for the Third Quarter of 2023Prostatype Genomics AB (publ) provided revenue guidance for the third quarter of 2023. The Company also projects that revenue growth will return to positive trend in the Third Quarter.
Buying Opportunity • Jul 13Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be €0.038, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 2,779% in 2 years. Earnings is forecast to grow by 36% in the next 2 years.
お知らせ • Jun 21Prostatype Genomics AB Appoints Gerald Andriole as Chief Medical OfficerProstatype Genomics AB announced that Professor Gerald Andriole has been appointed as global Chief Medical Officer at Prostatype Genomics. With more than 35 years in urology, Professor Andriole brings a wealth of experience and expertise to Prostatype Genomics as the company works towards commercializing the Prostatype® test in the United States and globally. Gerald L. Andriole, Jr., MD, was most recently Professor in the Department of Urology and Director of the Brady Urological Institute in the National Capital Region of Johns Hopkins University. Previously, he was the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine in St. Louis, Missouri. Professor Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He completed urology residency at Brigham and Women's Hospital and Harvard Medical School, Boston, MA. He then received specialty training in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland. Professor Andriole has over 35 years of consistent contributions in caring for men with prostate cancer and in prostate cancer prevention, screening and treatment research. He has contributed more than 450 peer-reviewed publications and has served on the editorial boards of several prestigious medical journals. He has been Chairman of the Prostate Committee of the National Cancer Institute's Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial; Chairman of the Prostate Committee for the Society of Urologic Oncology Clinical Trials Consortium; and Chairman of the Steering Committee of the REDUCE International Prostate Cancer Prevention Trial. Professor Andriole has been the recipient of numerous awards including the outstanding achievement award from the Urologic Oncology Branch of the National Cancer Institute, the Distinguished Clinician Award from Washington University in St. Louis and the Richard Williams Award for Prostate Cancer Research Excellence from the American Urologic Association Urology Care Foundation.
Reported Earnings • Jun 02First quarter 2023 earnings releasedFirst quarter 2023 results: Net loss: kr7.81m (loss widened 41% from 1Q 2022).
お知らせ • Jun 02+ 1 more updateProstatype Genomics AB (Publ) Announces Executive ChangesProstatype Genomics AB (publ) announced executive changes. The company announced election of Henrik Nilsson as new member of the board and Karlheinz Schmelig was not available for re-election.
お知らせ • May 13Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 17.787846 million.Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 17.787846 million. Security Name: Shares Security Type: Common Stock Securities Offered: 71,151,384 Price\Range: SEK 0.25 Transaction Features: Rights Offering
お知らせ • May 06Prostatype Genomics AB Appoints Professor Gerald Andriole as Chief Medical OfficerProstatype Genomics AB announced that Professor Gerald Andriole has been appointed as global Chief Medical Officer at Prostatype Genomics. With more than 35 years in urology, Professor Andriole brings a wealth of experience and expertise to Prostatype Genomics as the company works towards commercializing the Prostatype® test in the United States and globally. Gerald L. Andriole, Jr., MD, was most recently Professor in the Department of Urology and Director of the Brady Urological Institute in the National Capital Region of Johns Hopkins University. Previously, he was the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine in St. Louis, Missouri. Professor Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He completed urology residency at Brigham and Women's Hospital and Harvard Medical School, Boston, MA. He then received specialty training in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland. Professor Andriole has over 35 years of consistent contributions in caring for men with prostate cancer and in prostate cancer prevention, screening and treatment research. He has contributed more than 450 peer-reviewed publications and has served on the editorial boards of several prestigious medical journals. He has been Chairman of the Prostate Committee of the National Cancer Institute's Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial; Chairman of the Prostate Committee for the Society of Urologic Oncology Clinical Trials Consortium; and Chairman of the Steering Committee of the REDUCE International Prostate Cancer Prevention Trial.
Reported Earnings • Feb 18Full year 2022 earnings released: kr1.27 loss per share (vs kr1.11 loss in FY 2021)Full year 2022 results: kr1.27 loss per share (further deteriorated from kr1.11 loss in FY 2021). Net loss: kr29.1m (loss widened 86% from FY 2021).
お知らせ • Feb 17Prostatype Genomics AB (publ) to Report Fiscal Year 2022 Results on May 04, 2023Prostatype Genomics AB (publ) announced that they will report fiscal year 2022 results on May 04, 2023
お知らせ • Feb 16+ 4 more updatesProstatype Genomics AB (publ) to Report Q2, 2023 Results on Aug 17, 2023Prostatype Genomics AB (publ) announced that they will report Q2, 2023 results on Aug 17, 2023
お知らせ • Jan 12Prostatype Genomics Appoints Steven Gaal as PresidentProstatype Genomics AB (publ) has recruited Steven Gaal to the role of President of the company's wholly owned subsidiary, Prostatype Genomics Inc. Steven's task will be to establish and launch Prostatype®, the company's genomic test to assess the aggressiveness of prostate cancer in individual patients, in the US market. Steven has over 18 years of experience from leading positions in the sale of cancer diagnostic tools and services and begins his employment with Prostatype Genomics Inc. effective immediately. Steven comes to Prostatype Genomics Inc. with extensive experience in genomic testing. Steven has held positions in both early stage companies as well as established companies. He has held senior leadership positions with USLABS (acquired by LabCorp), P4Diagnostix and most recently SkylineDx. As VP of Sales at MDxHealth Steven was instrumental in the launch of ConfirmMDx for Prostate Cancer and SelectMDx for Prostate Cancer to US based Urologists.
お知らせ • Nov 08Prostatype Genomics AB (Publ) Provides Sales Guidance for the Year 2022Prostatype Genomics AB (publ) provided sales guidance for the year 2022. Sales in 2022 are estimated to amount to SEK 700,000.
お知らせ • Oct 19Prostatype Genomics Announces Management ChangesOn November 8, 2022 Emelie will take over the important role of CTO of Prostatype Genomics from Lidi Xu, who has held the position since 2019. Lidi is leaving the company to move back to China with her family but will continue to work on various projects for Prostatype Genomics. Emelie Berglund has a PhD in Biotechnology from the Royal Institute of Technology in Stockholm, and more than seven years of combined research experience within prostate cancer. After her degree, Emelie has led the R&D operations of a Swedish life science company that develops products in cancer detection and biomarker analysis. Emelie's main tasks will be to strengthen the scientific footprint of Prostatype Genomics by initiating, running, and coordinating validation studies around the world, ensuring that the results are published in the right channels and working with product development of the Prostatype® Test System, the company's product for prognosticating the aggressiveness of a prostate cancer. Emelie's focus areas are in line with previously communicated objectives from Prostatype Genomics. Emelie will also work in close collaboration with the commercial part of the company as there is great interest in Prostatype® in all priority markets. The company is currently in advanced discussions with leading urologists who have already used and evaluated Prostatype® and is on its way to a more routine use of the product. The increased use of Prostatype® has led to a significant influx of further contacts with customers, where Emelie's skills and experience will ensure that the company continue to deliver a continued good service also in terms of the scientific discussions.
お知らせ • Sep 16Prostatype Shows Strong Data in Asian Pilot StudyWith the second independent pilot study in the East Asia region showing strong clinical performance, Prostatype Genomics is now reviewing commercialization opportunities in the region. The recent study was conducted in China in collaboration with the Nanjing Drum Tower University Hospital, Jiangsu, and Prostatype Genomics' partner GloriousMed based in Shanghai. The study indicates that the clinical performance of Prostatype® in East Asian population is in line with the results previously communicated results in several studies in Caucasian populations. Strong predictive performance: In total 108 patients were included in the pilot study. All patients who either died from prostate cancer or developed metastasis were identified as "high-risk patients" according to the Prostatype® risk score (P-score) algorithm. The algorithm developed by Prostatype Genomics where the patients genetic information from genes closest associated with aggressive prostate cancer is added together with other relevant clinical parameters to form the P-score. In addition, more than 26% of the patients (28 patients in total) were downgraded from a higher risk group to a lower risk group which is clinically important as it often results in different treatment options. The median follow-up time was 5.3 years from diagnosis. finalized two independent pilot studies in the East Asia region showing robust clinical performance by Prostatype. Based on the previous strong results from the ongoing more comprehensive validation study in Taiwan, the company are encouraged by the opportunities these results give Prostatype Genomics in the large and commercially interesting market of East Asia. Company are currently reviewing the specific commercialization opportunities in the region. The ongoing challenges with Covid-19 in China and other countries in East Asia, including difficulties to travel due to Covid-restrictions, will decide how quickly company will be able to move forward in this specific market. The results of the study will be presented at the Chinese Urology Association's national congress on September 21-25, by Dr. Zhang Shun from the Nanjing Drum Tower Hospital.
Reported Earnings • Aug 19Second quarter 2022 earnings releasedSecond quarter 2022 results: Net loss: kr7.39m (loss widened 213% from 2Q 2021). Over the next year, revenue is forecast to grow 1,278%, compared to a 11% growth forecast for the Biotechs industry in Germany.
Board Change • Jul 31High number of new directorsDirector Mattias Prage was the last director to join the board, commencing their role in 2022.
お知らせ • Jun 03Prostatype Genomics AB (Publ) Appoints Mattias Prage as Member of the BoardProstatype Genomics AB (publ) at its annual general meeting held on June 2, 2022, Mattias Prage was elected as new member of the board.
Reported Earnings • May 14First quarter 2022 earnings releasedFirst quarter 2022 results: Net loss: kr5.56m (loss widened 62% from 1Q 2021). Over the next year, revenue is forecast to grow 603%, compared to a 36% growth forecast for the industry in Germany.
Board Change • May 12Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Hakan Englund was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 25+ 5 more updatesProstatype Genomics AB (publ) to Report Q3, 2022 Results on Nov 10, 2022Prostatype Genomics AB (publ) announced that they will report Q3, 2022 results on Nov 10, 2022
Board Change • Feb 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Hakan Englund was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 19Third quarter 2021 earnings releasedThird quarter 2021 results: Net loss: kr3.66m (loss narrowed 23% from 3Q 2020).
お知らせ • Aug 28Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 24.724583 million.Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 24.724583 million. Security Name: Shares Security Type: Common Stock Securities Offered: 1,901,891 Price\Range: SEK 13 Transaction Features: Subsequent Direct Listing
Reported Earnings • Aug 21Second quarter 2021 earnings released: kr0.18 loss per share (vs kr0.42 loss in 2Q 2020)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: kr549.0k (down 50% from 2Q 2020). Net loss: kr2.36m (loss narrowed 51% from 2Q 2020).
